Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pediatric Endocrinology · Isolated Growth Hormone Deficiency

Standard Treatment: Growth Hormone Therapy

At a Glance

The standard treatment for isolated growth hormone deficiency (IGHD) is recombinant human growth hormone therapy. Treatment is administered via daily or once-weekly injections, with endocrinologists adjusting the weight-based dose by monitoring growth velocity and IGF-1 blood levels.

The standard of care for Isolated Growth Hormone Deficiency (IGHD) is replacement therapy with recombinant human growth hormone (rhGH). Because your child’s body isn’t making enough of this vital hormone, doctors provide a synthetic version that is identical to the one produced by the pituitary gland [1]. The goal of treatment is to “catch up” on growth, normalize height velocity, and support healthy metabolism and bone strength [2][3].

Treatment Options: Daily vs. Weekly

For many years, the only option was a daily injection. Today, parents and doctors can choose between two main approaches:

  • Daily Injections: These have a long history of safety and effectiveness. They are typically given just before bedtime to mimic the body’s natural nighttime release of growth hormone [4]. Rather than intimidating syringes, these are typically subcutaneous (under the skin) injections given with small, virtually painless needles using user-friendly, hidden auto-injector pens, which significantly reduces anxiety for both parents and children [4].
  • Once-Weekly (Long-Acting) GH: Newer formulations (such as somatrogon or lonapegsomatropin) stay in the system longer, allowing for just one injection per week [5]. Studies show that these are just as effective as daily shots and significantly reduce the “treatment burden” for families [6][7].

Parents typically begin to see noticeable “catch-up” growth within the first 3 to 6 months of therapy [2].

Note on Insurance and Cost: Growth hormone therapy is notoriously expensive and heavily gated by insurance companies. It almost always requires a strict “prior authorization” process, which can create a delay of several weeks or months between diagnosis and starting treatment. Setting realistic expectations for this timeline is helpful.

Dosing and Monitoring

Dosing in children is usually weight-based [8]. As your child grows, their dose will naturally need to increase. To ensure the dose is just right—effective but safe—the endocrinologist will monitor two key markers:

  1. IGF-1 Levels: Growth hormone tells the liver to produce a secondary hormone called Insulin-like Growth Factor 1 (IGF-1). Doctors measure this in the blood to check if the body is responding correctly to the medication [9][10]. They look at the IGF-1 SDS (Standard Deviation Score) to see how your child compares to other children of the same age and sex [9].
  2. Growth Velocity: The most important indicator of success is how many centimeters your child grows each year. Earlier initiation of therapy usually leads to better overall results [11][2].

Special Considerations for Type IA: The Backup Plan

As discussed in the genetics section, children with Type IA IGHD are at high risk of developing neutralizing anti-GH antibodies [12]. If these antibodies appear, they “block” the rhGH, and growth may stall completely [13].

If this occurs, the standard treatment is switched to mecasermin (rhIGF-1) [14]. Since the body is effectively “immune” to growth hormone, mecasermin provides the IGF-1 directly to keep the child growing [12][13].

Safety and Side Effects

While rhGH is generally well-tolerated, parents should be aware of a few rare but important side effects:

  • Scoliosis Progression: Because rhGH induces rapid catch-up growth, it can uncover or worsen existing spinal curvatures (scoliosis). Your doctor will regularly check your child’s spine during appointments [15].
  • Slipped Capital Femoral Epiphysis (SCFE): This is an orthopedic issue where the “ball” of the hip joint slips. It is more common during rapid growth spurts [15]. If your child develops a limp or complains of persistent hip or knee pain, contact your doctor [16].
  • Idiopathic Intracranial Hypertension (IIH): Rarely, growth hormone can cause increased pressure around the brain. Symptoms include severe, persistent headaches (often in the morning) and vision changes [17][18].
  • Hypoglycemia (with rhIGF-1): If a child is on mecasermin (rhIGF-1) rather than standard GH, the most significant risk is hypoglycemia (low blood sugar), so the medication must be given shortly after a meal [19][20].

Consistent follow-up appointments (typically every 3 to 6 months) allow the medical team to monitor these risks and adjust the treatment plan as your child grows [21].

Common questions in this guide

What is the standard treatment for isolated growth hormone deficiency?
The standard treatment is replacement therapy with recombinant human growth hormone (rhGH). This synthetic hormone is identical to what the body produces naturally and helps children catch up on growth, normalize height velocity, and support healthy bone strength.
Can my child take growth hormone once a week instead of daily?
Yes, newer long-acting formulations like somatrogon or lonapegsomatropin allow for a single weekly injection instead of daily shots. Studies show these once-weekly options are just as effective for growth and can significantly reduce the treatment burden for families.
How do doctors know if the growth hormone dose is correct?
Endocrinologists monitor your child's growth velocity and measure Insulin-like Growth Factor 1 (IGF-1) levels in their blood. The medication dose is typically based on your child's weight and will be carefully increased as they grow.
What are the possible side effects of growth hormone therapy?
While generally safe, rapid growth from therapy can sometimes reveal or worsen scoliosis or cause hip issues like slipped capital femoral epiphysis. Rarely, it may cause increased pressure around the brain, leading to severe morning headaches or vision changes.
What happens if my child with Type IA stops responding to growth hormone?
Children with Type IA IGHD can sometimes develop antibodies that block standard growth hormone. If this happens, doctors typically switch treatment to mecasermin (rhIGF-1), which provides the necessary growth factors directly to keep your child growing.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my child's starting dose of rhGH, and is it based on their weight or the severity of their deficiency?
  2. 2.Would my child be a good candidate for once-weekly long-acting growth hormone instead of daily injections?
  3. 3.How often will we check my child's IGF-1 levels, and what 'SDS' range are you aiming for?
  4. 4.What symptoms of slipped capital femoral epiphysis (SCFE) or intracranial hypertension (IIH) should I look for?
  5. 5.If my child has Type IA, how quickly would we know if they are developing neutralizing antibodies?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Isolated growth hormone deficiency due to the R183H mutation in GH1: Clinical analysis of a four-generation family.

    Cabrera-Salcedo C, Shah AS, Andrew M, et al.

    Clinical endocrinology 2017; (87(6)):874-876 doi:10.1111/cen.13400.

    PMID: 28626954
  2. 2

    Effect of adherence to growth hormone treatment on 0-2 year catch-up growth in children with growth hormone deficiency.

    van Dommelen P, Koledova E, Wit JM

    PloS one 2018; (13(10)):e0206009 doi:10.1371/journal.pone.0206009.

    PMID: 30356273
  3. 3

    Preliminary study of longitudinal changes in the pituitary and brain of children on growth hormone therapy.

    Low LS, Wong JHD, Tan LK, et al.

    Journal of neuroradiology = Journal de neuroradiologie 2023; (50(2)):271-277 doi:10.1016/j.neurad.2021.11.004.

    PMID: 34800564
  4. 4

    Recombinant growth hormone improves growth and adult height: a comparison between treated and untreated patients with idiopathic growth hormone deficiency.

    Zhao Q, Li R, Shao Q, et al.

    Translational pediatrics 2025; (14(3)):442-451 doi:10.21037/tp-2024-576.

    PMID: 40225070
  5. 5

    Long acting growth hormone (LAGH), an update.

    Grillo MS, Frank J, Saenger P

    Frontiers in pediatrics 2023; (11()):1254231 doi:10.3389/fped.2023.1254231.

    PMID: 37842029
  6. 6

    Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.

    Deal CL, Steelman J, Vlachopapadopoulou E, et al.

    The Journal of clinical endocrinology and metabolism 2022; (107(7)):e2717-e2728 doi:10.1210/clinem/dgac220.

    PMID: 35405011
  7. 7

    Somatrogon: First Approval.

    Lamb YN

    Drugs 2022; (82(2)):227-234 doi:10.1007/s40265-021-01663-2.

    PMID: 35041176
  8. 8

    The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.

    Liang Y, Zhang C, Wei H, et al.

    Frontiers in endocrinology 2022; (13()):922304 doi:10.3389/fendo.2022.922304.

    PMID: 36034448
  9. 9

    Insulin-like growth factor-1 level is a poor diagnostic indicator of growth hormone deficiency.

    Iwayama H, Kitagawa S, Sada J, et al.

    Scientific reports 2021; (11(1)):16159 doi:10.1038/s41598-021-95632-0.

    PMID: 34373538
  10. 10

    Relationship between 25-hydroxyvitamin D and IGF1: a cross-sectional study of the Third National Health and Nutrition Examination Survey participants.

    Li W, Yu T

    Journal of health, population, and nutrition 2023; (42(1)):35 doi:10.1186/s41043-023-00374-6.

    PMID: 37072869
  11. 11

    Response to Recombinant Human Growth Hormone (rhGH) Therapy in Children with Growth Hormone Deficiency.

    Riaz M, Ibrahim MN, Rai VR, et al.

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2024; (34(8)):932-935 doi:10.29271/jcpsp.2024.08.932.

    PMID: 39113512
  12. 12

    Recombinant Human Insulin-Like Growth Factor-1 Treatment of Severe Growth Failure in Three Siblings with STAT5B Deficiency.

    Muthuvel G, Al Remeithi SS, Foley C, et al.

    Hormone research in paediatrics 2024; (97(2)):195-202 doi:10.1159/000531491.

    PMID: 37586336
  13. 13

    Recombinant IGF-I: Past, present and future.

    Bright GM

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2016; (28()):62-5.

    PMID: 26822565
  14. 14

    Phosphoglucomutase 1 deficiency misdiagnosed as Laron syndrome.

    Uçaktürk SA, Özer E, Ceylan AC, Mengen E

    Journal of pediatric endocrinology & metabolism : JPEM 2026; (39(2)):199-203 doi:10.1515/jpem-2025-0447.

    PMID: 41099230
  15. 15

    Strong Association Between Growth Hormone Therapy and Proximal Tibial Physeal Avulsion Fractures in Children and Adolescents: A Case-Control Study.

    Beber SA, Gross PW, Nichols E, et al.

    The Journal of bone and joint surgery. American volume 2024; (106(3)):227-231 doi:10.2106/JBJS.23.00741.

    PMID: 38127811
  16. 16

    Little League Shoulder and Subsequent Proximal Humeral Fracture in the Setting of Human Growth Hormone Use: A Case Report.

    Kosko B, Richey B, Cardin S, et al.

    JBJS case connector 2023; (13(3)) doi:10.2106/JBJS.CC.22.00612.

    PMID: 37556574
  17. 17

    GH and IGF-1 Replacement in Children.

    Pfäffle R, Kiess W

    Handbook of experimental pharmacology 2020; (261()):67-86 doi:10.1007/164_2019_337.

    PMID: 31932988
  18. 18

    The history, physiology and treatment safety of growth hormone.

    Tidblad A

    Acta paediatrica (Oslo, Norway : 1992) 2022; (111(2)):215-224 doi:10.1111/apa.15948.

    PMID: 34028879
  19. 19

    Pubertal Timing and Growth Dynamics in Children With Severe Primary IGF-1 Deficiency: Results From the European Increlex® Growth Forum Database Registry.

    Bang P, Polak M, Perrot V, et al.

    Frontiers in endocrinology 2022; (13()):812568 doi:10.3389/fendo.2022.812568.

    PMID: 35250870
  20. 20

    Adult height and long-term outcomes after rhIGF-1 therapy in two patients with PAPP-A2 deficiency.

    Martín-Rivada Á, Barrios V, Martínez Díaz-Guerra G, et al.

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2021; (60-61()):101419 doi:10.1016/j.ghir.2021.101419.

    PMID: 34358737
  21. 21

    Screening a large pediatric cohort with GH deficiency for mutations in genes regulating pituitary development and GH secretion: Frequencies, phenotypes and growth outcomes.

    Blum WF, Klammt J, Amselem S, et al.

    EBioMedicine 2018; (36()):390-400 doi:10.1016/j.ebiom.2018.09.026.

    PMID: 30266296

This page provides educational information about pediatric IGHD treatments and growth hormone therapy. It does not replace professional medical advice from your child's pediatric endocrinologist.

Get notified when new evidence is published on Non-acquired isolated growth hormone deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.